The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of K+/Cl-cotransporter (Kcc2/KCC2) gene expression enhancer to a subject in need.

Method of making a cross metathesis product, the method comprising at least step (X) or step (Y): (X) reacting in a cross metathesis reaction a first compound comprising a terminal olefinic group with a second compound comprising a terminal olefinic group, wherein the first and the second compound may be identical or may be different from one another; or (Y) reacting in a ring-closing metathesis reaction two terminal olefinic groups which are comprised in a third compound; wherein the reacting in step (X) or step (Y) is performed in the presence of a ruthenium carbene complex comprising a [Ru═C]-moiety and an internal olefin.

Method of making a cross metathesis product, the method comprising at least step (X) or step (Y): (X) reacting in a cross metathesis reaction a first compound comprising a terminal olefinic group with a second compound comprising a terminal olefinic group, wherein the first and the second compound may be identical or may be different from one another; or (Y) reacting in a ring-closing metathesis reaction two terminal olefinic groups which are comprised in a third compound; wherein the reacting in step (X) or step (Y) is performed in the presence of a ruthenium carbene complex comprising a [Ru═C]-moiety and an internal olefin.

The present disclosure provides compositions comprising delta lactones for use in improving taste in food products.

The present disclosure provides compositions comprising delta lactones for use in improving taste in food products.

The invention relates to processes for preparing Carboprost or Carboprost Tromethamine, and intermediates prepared from the process, and 5,6-trans isomer free Carboprost or Carboprost Tromethamine prepared therefrom. The invention also relates to a novel crystalline form of Carboprost Tromethamine.

The invention relates to processes for preparing Carboprost or Carboprost Tromethamine, and intermediates prepared from the process, and 5,6-trans isomer free Carboprost or Carboprost Tromethamine prepared therefrom. The invention also relates to a novel crystalline form of Carboprost Tromethamine.

Described herein is a composition of matter including a) 0.5 to 85% w/w of (Z)-oxacyclohexadec-12-en-2-one; b) 0.5 to 30% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 30% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0.5 to 85% w/w of (Z)-oxacyclohexadec-13-en-2-one, the percentage being relative to the total weight of the composition of matter; wherein the weight ratio of the E-diastereoisomers to the Z-diastereoisomers is in the range between 40:60 and 15:85.

Described herein is a composition of matter including a) 0.5 to 85% w/w of (Z)-oxacyclohexadec-12-en-2-one; b) 0.5 to 30% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 30% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0.5 to 85% w/w of (Z)-oxacyclohexadec-13-en-2-one, the percentage being relative to the total weight of the composition of matter; wherein the weight ratio of the E-diastereoisomers to the Z-diastereoisomers is in the range between 40:60 and 15:85.

The invention relates to processes for preparing Carboprost or Carboprost Tromethamine, and intermediates prepared from the process, and 5,6-trans isomer free Carboprost or Carboprost Tromethamine prepared therefrom. The invention also relates to a novel crystalline form of Carboprost Tromethamine.